SCHEMBL25811432

SCHEMBL25811432

CC1=C(C)C(S(=O)(=O)c2ccccc2)c2ccc(CO)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.36
KAT6A Q92794 2/20 0.35
ALDH1A1 P00352 2/20 0.34
CHEK1 O14757 1/20 0.34
NR1I2 O75469 1/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
AKR1C3 P42330 1/20 0.34
RORC P51449 1/20 0.34
PTGES2 Q9H7Z7 2/20 0.33
MALT1 Q9UDY8 1/20 0.33
IKBKB O14920 1/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812882 0.84 ELANE (0.39) KAT6AALDH1A1AKR1C3CA1CA2
SCHEMBL25812739 0.82 NAT1 (0.38) HTR6ALDH1A1HSD17B10CA1CA2
SCHEMBL25811437 0.80 NAT1 (0.35) ALDH1A1CA1CA2CA12CA9
SCHEMBL25811421 0.77 PTGS2 (0.46) GAACA1CA2CA12CA5A
SCHEMBL16383945 0.67 ELANE (0.42) KAT6AALDH1A1GAACA1CA2
SCHEMBL646928 0.63 ALDH1A1 (0.50) ALDH1A1GAAHSD17B10PTGES2IKBKB
SCHEMBL1134311 0.63 ENPP2 (0.52) HTR6ALDH1A1HSD17B10PTGES2IKBKB
SCHEMBL2208511 0.63 ESR2 (0.46) ALDH1A1GAA
SCHEMBL1138968 0.63 METAP2 (0.52) ALDH1A1HSD17B10
SCHEMBL710751 0.63 HTR6 (0.61) HTR6NR1I2CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 HTR6 14/4885KAT6A 452/4885ALDH1A1 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.